Jim Cramer, is one of the best financial analysts and investing advisors from ‘The Street’ has repeatedly recommended three companies and that too as recently as within the month gone by. What is it that has brought these companies into limelight? Each one of them is renowned in its niche, courtesy of innovations and good returns for shareholders, but their analysis is as follows –
1. Chipotle’s Mexican Grill Inc (NYSE:CMG)
Even though the price of avocados, beans and rice may have shot up during the latest month, California’s most loved chain of Mexican specialty restaurants, Chipotle’s Mexican Grill Inc (NYSE:CMG) announced that they would not reflect the hike in their menus. Thanks to this promise, Americans will now continue to enjoy their Mexican green delicacies. In spite of the fact that the state’s agriculture is bearing the brunt of a drought, Chipotle remains largely unaffected because it has other alternatives to source its ingredients from. With the rise in popularity of Mexican traditional food, there is no doubt that Chipotle Mexican Grill Inc (NYSE:CMG) will trace a northward trajectory on the charts.
2. Apple Inc (NASDAQ:AAPL)
Apple Inc (NASDAQ:AAPL) is about to release its latest innovation, iPhone 6 in September. Although there are indications that the launch may be delayed up till October, the enthusiasm of people remains as contagious as ever. What actually matters is the fact that the new device looks promising to people who “know things”. Besides, the fact that Apple Inc (NASDAQ:AAPL) might launch their iWatch at around the same time is also a distinct possibility. With iPhone 6 and iWatch due to be released, it is but natural for Apple Inc (NASDAQ:AAPL) to be a must-buy at the moment.
3. Celgene Corporation (NASDAQ:CELG)
Jim Cramer also recommends new companies that have entered the pharmaceutical arena. Why is Celgene Corporation (NASDAQ:CELG) better than the existing giants namely Pfizer Inc (NYSE:PFE) or Eli Lilly & Co (NYSE:LLY)? It is simply because this company is on the verge of discovering revolutionary therapies, and its new pills have been swiftly approved by regulatory authorities in USA. While these are already on circulation in USA, it is likely that they would soon be approved and prescribed in Europe and Asia too. Abraxaner and Otezla are a couple of Celgene Corporation (NASDAQ:CELG)’s products that have hit the American markets lately, but there are likely to be more in near future that we should look out for.
This article has been written by Michael Stan and edited by Vinita Basu.